Cassava Sciences Inc vs Liberty Media Corporation Series C Liberty Formula One Common Stock — how do they compare? Cassava Sciences Inc trades at $0.71 (market cap $35.91M), while Liberty Media Corporation Series C Liberty Formula One Common Stock trades at $90.85 (market cap $23.11B). The key difference: Liberty Media Corporation Series C Liberty Formula One Common Stock is far larger — about 643.6× Cassava Sciences Inc's market cap, and Liberty Media Corporation Series C Liberty Formula One Common Stock is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 38 Days and Liberty Media Corporation Series C Liberty Formula One Common Stock for 0 Days on average.
| FLNA | FWONK | |
|---|---|---|
Market Cap | $35.91M | $23.11B |
Volume | 323,246 | 3,394,596 |
Sector | Health | Media |
52-Week High | $4.64 | $106.66 |
52-Week Low | $0.68 | $81.42 |
Typical Hold Time | 38 Days | 0 Days |
Enterprise Value | -$46.77M | $26.57B |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.7316, down 4.93% today, amid bearish technical signals despite recent FDA progress. The stock shows negative profitability with ROE at -55.79% and consistent negative cash flow, though it has beaten EPS estimates for three consecutive quarters. Analyst consensus remains positive with 8 buy ratings versus 4 holds.
The outlook hinges on clinical development success, particularly the Phase 2a study for TSC-related epilepsy. Investment opportunity exists if trials progress favorably, but risks include cash burn, regulatory hurdles, and persistent losses. Current valuation metrics like EV/EBITDA of 1.11 suggest potential upside if execution improves.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Liberty Media Corporation's Series C Liberty Formula One common stock is a tracking stock reflecting the economic performance of the Formula One Group, which holds Liberty Media's interests in Formula 1 racing, MotoGP, and related minority investments.
Read more on FWONK →